KIRKLAND, QC, April 29, 2015 /CNW Telbec/ - Valeo Pharma Inc, a Canadian Specialty Pharmaceutical Company, announces today the launch of its new corporate website. Reflecting Valeo Pharma's strategic shift to a Canadian Specialty Pharmaceutical Company, the website outlines the new focus for the organization, and introduces the product portfolio.
"2014 was a transformative year for Valeo Pharma with the sale of our Dermatology Products and the addition of Synacthen® Depot," said Steve Saviuk, President and Founder of Valeo Pharma. "The website presents our dedication to registering and marketing innovative Specialty Pharmaceutical Products in Canada."
Valeo Pharma is building a pipeline of prescription products in Oncology, Neurodegenerative Diseases, and Infectious Diseases, with an emphasis on drugs to treat Rare/Orphan Diseases. With all resources in-house to bring a product to market, Valeo Pharma is well positioned to be the partner of choice for International pharmaceutical companies looking for options to launch innovative prescription products in Canada.
About Valeo Pharma
Valeo Pharma is a privately-held Canadian specialty pharmaceutical company founded on the commitment of providing healthcare professionals and patients with high quality products and services. Working with International developers and manufacturers, Valeo Pharma offers a comprehensive suite of services to launch products in the Canadian market.
SOURCE Valeo Pharma
Image with caption: "Valeo Pharma (CNW Group/Valeo Pharma)". Image available at: http://photos.newswire.ca/images/download/20150429_C7526_PHOTO_EN_15928.jpg
For further information: Company Contact: Marc Leger, Executive VP Commercial Operations, Valeo Pharma Inc. 855-694-0151, [email protected]